Drug Trial Radar · NCT07288112
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
35
Planned (sponsor's estimate)
Start
Apr 6, 2026
Primary completion
Jan 2031
Study completion Jan 2033
Sponsor
- Lead sponsor
- Diakonos Oncology CorporationIndustry
- Sponsor type
- Industry
- First posted
- Dec 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if DOC1021 + pIFN will be safe and will lead to tumor responses in patients with refractory melanoma. DOC1021 is a dendritic cell immunotherapy derived from a patient's own blood cells and loaded with antigens from the patient's tumor in the form of tumor lysate and mRNA. The goal is to stimulate a T cell immune response that eliminates tumor cells. The study consists of two components: an initial phase I safety study to confirm safety/tolerability of the treatment regimen, and, subsequently, a single-arm phase II cohort to assess efficacy of the treatment regimen. All participants will: * Undergo a leukapheresis collection (take filgrastim subcutaneously x 5 doses, if clinically necessary, leading up to collection) * Receive two doses of DOC1021 under image guidance 2 weeks apart * Receive subcutaneous pIFN injections weekly for a total of 4 doses in parallel with the DOC1021 injections * Undergo an optional image-guided perinodal DOC1021 booster injection approximately 6 months after the first DOC1021 dose along with additional subcutaneous pIFN injections at time of the booster and the subsequent week for a total of 2 pIFN doses * Visit the clinic regularly to assess quality of life, symptoms, medication use, imaging, bloodwork, and to receive optional treatment with anti-PD1 agents
Conditions
- Refractory Melanoma
Interventions
DOC1021Biological
Double-loaded dendritic cell vaccine, loaded with tumor lysate and mRNA using proprietary method
Tumor resectionProcedure
Tumor resection or biopsy
pIFN (peginterferon alfa-2a)Drug
pIFN 180 mcg subcutaneously every week for 4 total doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I: To evaluate the number of dose limiting toxicities reportedTime frame: From time of first DOC1021 dose administration to 6 weeks later
- Phase II: To evaluate the objective response rate (ORR) as the proportion of patients with a confirmed complete response (CR) or partial response (PR) to treatment, as per RECIST 1.1 criteriaTime frame: 5 years
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
The University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Banner MD Anderson Cancer Center
Gilbert, Arizona · Recruiting
Arizona State University-Honor Health Research Institute
Scottsdale, Arizona · Recruiting
City of Hope
Duarte, California · Recruiting
Massachusetts General Hospital Cancer Institute
Boston, Massachusetts · Recruiting
Atlantic Health
Morristown, New Jersey · Recruiting
University of North Carolina
Chapel Hill, North Carolina · Recruiting
UT Southwestern
Dallas, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.